In Uncategorized Posted
TBVI Awardees 2025
With the TBVI Award, TBVI encourages promising scientists and rewards their remarkable contributions to tuberculosis (TB) vaccine research and development, by offering them the opportunity to [...]
With the TBVI Award, TBVI encourages promising scientists and rewards their remarkable contributions to tuberculosis (TB) vaccine research and development, by offering them the opportunity to [...]
Would you like to present your work at the TBVI Annual Symposium? To encourage promising scientists and recognise outstanding contributions to TB vaccine research and development, TBVI presents [...]
Following the call for vaccine researchers to submit their vaccine candidate for testing in a mouse model, we are delighted to announce the selection of three candidates. Based on predetermined [...]
On May 27-28 2024, the second progress meeting of the MTBVACN3 project took place in Pilanesberg, near Johannesburg in South Africa. During these days the consortium partners met to share [...]
Biofabri and TBVI have signed a contract with the European Health and Digital Executive Agency (HaDEA) under the EU4Health Programme to accelerate the final development of the MTBVAC vaccine. [...]
TBVI has an exciting career opportunity for a motivated individual to join the organisation as Scientific Project Manager (full-time or part-time). You will join a small, enthusiastic team, [...]
TBVI has an exciting position as Management Assistant (full-time or part-time). You will join a small, enthusiastic team, dedicated to TBVI’s goals to relieve the burden of TB and eliminate [...]
As we believe that no one should be left out of the conversation, we offer travel and registration support (participant support) for participants planning to attend the 7th Global Forum on TB [...]
Diversification of the vaccine development pipeline has been identified as a priority area in the Global TB Vaccine R&D Roadmap. The TBVAC-HORIZON consortium aims, amongst other things, to [...]
TBVAC-HORIZON has met an important milestone: On 3 April 2024, the first participant in the UOXF “TB46” study was enrolled. Tuberculosis (TB) remains one of the most devastating infectious [...]
Runderweg 6
8219 PK Lelystad
The Netherlands
Email: info@tbvi.eu
Phone: 0031 (0)6 1099 5196